Cellectar Biosciences flags going concern in 10-Q filing
Alpha Vantage · Quantisnow · · AI-summarised by FinFlash
Cellectar Biosciences filed its Q3 2026 10-Q, reporting a nine-month net loss of roughly $21 million and an accumulated deficit of $290 million as of September 30, 2026, alongside a going-concern warning. The pre-revenue company said it will keep incurring losses until its product candidates are approved and commercialized. Investors face dilution and financing risk before any revenue arrives.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.